Crowd Funded Cures’ mission is to incentivize clinical trials for off-patent therapies that are otherwise ignored because a monopoly price cannot be enforced with patents.
They are interested in conducting retrospective and self-funding prospective interventional pharmacoeconomic (IVPE) RCTs where a low-cost repurposed generic (e.g. ketamine) is compared to an expensive standard of care (e.g. esketamine for treatment resistant depression). If the difference in cost between both arms of the RCT exceeds the cost of running the RCT, it has a negative cost for a payer funding the trial. They have recently published a policy memo in the US on the use of a self-sustaining IVPE and Advance Market Commitment fund for generic drug repurposing using cost savings rather than tax revenue.